Rossby Financial LCC Invests $119,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Rossby Financial LCC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 35,000 shares of the company’s stock, valued at approximately $119,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Xeris Biopharma by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock valued at $26,778,000 after purchasing an additional 133,738 shares during the last quarter. Geode Capital Management LLC increased its position in Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after buying an additional 17,956 shares during the period. AIGH Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 17.8% during the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock worth $8,729,000 after buying an additional 389,192 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after acquiring an additional 500,120 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Xeris Biopharma by 166.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company’s stock worth $3,537,000 after acquiring an additional 651,481 shares during the period. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

XERS has been the topic of a number of analyst reports. Piper Sandler restated a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum lifted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Leerink Partners raised their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Xeris Biopharma Stock Up 5.3 %

Shares of XERS stock opened at $4.38 on Wednesday. The business has a fifty day simple moving average of $4.41 and a 200 day simple moving average of $3.67. The company has a market cap of $674.26 million, a P/E ratio of -9.73 and a beta of 1.37. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.69 and a twelve month high of $6.07.

Insiders Place Their Bets

In other news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.56% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.